JP2011527902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527902A5 JP2011527902A5 JP2011518030A JP2011518030A JP2011527902A5 JP 2011527902 A5 JP2011527902 A5 JP 2011527902A5 JP 2011518030 A JP2011518030 A JP 2011518030A JP 2011518030 A JP2011518030 A JP 2011518030A JP 2011527902 A5 JP2011527902 A5 JP 2011527902A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antibody
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 25
- 108090001123 antibodies Proteins 0.000 claims 25
- 101700027814 CDR3 Proteins 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 201000009910 diseases by infectious agent Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 230000035693 Fab Effects 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000002889 Endothelial Cells Anatomy 0.000 claims 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 210000004271 bone marrow stromal cells Anatomy 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002919 epithelial cells Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 230000003472 neutralizing Effects 0.000 claims 1
- 230000002207 retinal Effects 0.000 claims 1
- 235000020945 retinal Nutrition 0.000 claims 1
- 239000011604 retinal Substances 0.000 claims 1
Claims (16)
- hCMVタンパク質gBに特異的であり、hCMVの臨床分離株による内皮細胞、上皮細胞、網膜細胞、骨髄細胞、樹状細胞、線維芽細胞、または間葉系間質細胞の感染を中和する、単離された抗体またはその抗原結合断片であって、hCMVを90%中和するために必要とされる前記抗体の濃度は10μg/mL以下であり、8F9ではない、抗体またはその抗原結合断片。
- hCMVを90%中和するために必要とされる前記抗体の濃度は、1.2μg/mL以下である、請求項1に記載の抗体または断片。
- 配列番号348、328、334、290、294、308、357、314、もしくは367に対して少なくとも85%の配列同一性を有する重鎖可変領域、および/または、配列番号349、329、291、309、もしくは368に対して少なくとも85%の配列同一性を有する軽鎖可変領域を含み、hCMVタンパク質gBに特異的である、抗体またはその抗原結合断片。
- それぞれ配列番号328および329、それぞれ配列番号334および329、それぞれ配列番号290および291、それぞれ配列番号294および291、それぞれ配列番号357および291、それぞれ配列番号308および309、それぞれ配列番号314および309、またはそれぞれ配列番号367および368と、少なくとも85%同一であるアミノ酸配列を有する、重鎖および軽鎖可変領域を含む、請求項1〜3のうちのいずれか1項に記載の抗体または断片。
- それぞれ配列番号348および349と少なくとも85%同一であるアミノ酸配列を有する重鎖および軽鎖可変領域を含む、請求項1〜3のうちのいずれか1項に記載の抗体または断片。
- (a)配列番号336、337、および338に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号339、340、および341に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列;
(b)配列番号316、317、および318に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号319、320、および321に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列;
(c)配列番号316、317、および332に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号319、320、および321に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列;
(d)配列番号278、279、および280に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号281、282、および283に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列;
(e)配列番号352、279、および280に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号281、282、および283に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列;
(f)配列番号296、297、および298に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号299、300、および301に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列;
(g)配列番号296、312、および298に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号299、300、および301に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列;または、
(h)配列番号360、279、および280に記載される、それぞれ重鎖可変領域CDR1、CDR2、およびCDR3配列、ならびに配列番号281、282、および361に記載される、それぞれ軽鎖可変領域CDR1、CDR2、およびCDR3配列
を含み、hCMVタンパク質gBに特異的である、抗体またはその抗原結合断片。 - hCMV感染を中和し、請求項4または請求項5に記載の抗体または断片と同一のエピトープに結合するか、または請求項4または請求項5に記載の抗体または断片とhCMVへの結合を競合する、単離された抗体またはその抗原結合断片。
- 前記抗体は、ヒト抗体、モノクローナル抗体、単鎖抗体、Fab、Fab’、F(ab’)2、Fv、またはscFvである、請求項1〜7のうちのいずれか1項に記載の抗体または断片。
- hCMV感染の治療のための、請求項1〜8のうちのいずれか1項に記載の抗体または断片。
- 請求項3〜8のうちのいずれか1項に記載の抗体または断片をコードするヌクレオチド配列を含む、単離された核酸分子。
- 前記ヌクレオチド配列は、配列番号342〜347、350、351、322〜327、330、331、333、335、284〜289、292、293、295、353〜356、358、359、287、288、302〜307、310、311、313、315、362〜364、287、365、366、369、または370のうちのいずれか1つと少なくとも75%同一である、請求項10に記載の核酸分子。
- 請求項1〜8のうちのいずれか1項に記載の抗体または断片を発現する、細胞。
- 請求項1〜8のうちのいずれか1項に記載の抗体または断片、または請求項10もしくは11に記載の核酸と、薬学的に許容される希釈剤もしくは担体と、任意で、hCMV感染を中和する第2の抗体もしくはその抗原結合断片と、を含む、組成物。
- hCMV感染の治療のための医薬の製造における、請求項1〜8のうちのいずれか1項に記載の抗体または断片、または請求項10もしくは11に記載の核酸、または請求項13に記載の組成物の使用。
- 請求項1〜8のうちのいずれか1項に記載の抗体または断片を産生するための方法であって、(i)請求項12に記載の細胞を培養することと、(ii)前記抗体または断片を単離することと、を含む、方法。
- 第2の抗体が、hCMVタンパク質UL128;hCMVタンパク質gH;hCMVタンパク質gL;hCMVタンパク質gM;hCMVタンパク質gN;hCMVタンパク質gO;hCMVタンパク質UL128、UL130、およびUL131Aの組み合わせ;hCMVタンパク質UL130およびUL131Aの組み合わせ;hCMVタンパク質gH、gL、UL128、およびUL130の組み合わせ;hCMVタンパク質gMおよびgNの組み合わせ;ならびにhCMVタンパク質gB上の第2のエピトープ、から選択されるタンパク質またはタンパク質の組み合わせに結合する、請求項13に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8133408P | 2008-07-16 | 2008-07-16 | |
US61/081,334 | 2008-07-16 | ||
PCT/IB2009/006641 WO2010007533A2 (en) | 2008-07-16 | 2009-07-15 | Human cytomegalovirus neutralizing antibodies and use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013218791A Division JP5807050B2 (ja) | 2008-07-16 | 2013-10-22 | ヒトサイトメガロウイルス中和抗体およびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011527902A JP2011527902A (ja) | 2011-11-10 |
JP2011527902A5 true JP2011527902A5 (ja) | 2012-05-17 |
JP5422649B2 JP5422649B2 (ja) | 2014-02-19 |
Family
ID=41550776
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518030A Expired - Fee Related JP5422649B2 (ja) | 2008-07-16 | 2009-07-15 | ヒトサイトメガロウイルス中和抗体およびその使用 |
JP2013218791A Expired - Fee Related JP5807050B2 (ja) | 2008-07-16 | 2013-10-22 | ヒトサイトメガロウイルス中和抗体およびその使用 |
JP2015082325A Expired - Fee Related JP6062477B2 (ja) | 2008-07-16 | 2015-04-14 | ヒトサイトメガロウイルス中和抗体およびその使用 |
JP2016241815A Expired - Fee Related JP6345753B2 (ja) | 2008-07-16 | 2016-12-14 | ヒトサイトメガロウイルス中和抗体およびその使用 |
JP2018098457A Expired - Fee Related JP6703037B2 (ja) | 2008-07-16 | 2018-05-23 | ヒトサイトメガロウイルス中和抗体およびその使用 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013218791A Expired - Fee Related JP5807050B2 (ja) | 2008-07-16 | 2013-10-22 | ヒトサイトメガロウイルス中和抗体およびその使用 |
JP2015082325A Expired - Fee Related JP6062477B2 (ja) | 2008-07-16 | 2015-04-14 | ヒトサイトメガロウイルス中和抗体およびその使用 |
JP2016241815A Expired - Fee Related JP6345753B2 (ja) | 2008-07-16 | 2016-12-14 | ヒトサイトメガロウイルス中和抗体およびその使用 |
JP2018098457A Expired - Fee Related JP6703037B2 (ja) | 2008-07-16 | 2018-05-23 | ヒトサイトメガロウイルス中和抗体およびその使用 |
Country Status (31)
Country | Link |
---|---|
US (21) | US8603480B2 (ja) |
EP (3) | EP3178845A1 (ja) |
JP (5) | JP5422649B2 (ja) |
KR (1) | KR101356350B1 (ja) |
CN (3) | CN102203133B (ja) |
AU (1) | AU2009272284C1 (ja) |
BR (1) | BRPI0916443A2 (ja) |
CA (2) | CA2730776C (ja) |
CL (3) | CL2011000084A1 (ja) |
CO (1) | CO6351801A2 (ja) |
CR (2) | CR20160355A (ja) |
CU (1) | CU23953B1 (ja) |
DK (2) | DK2352759T3 (ja) |
EA (1) | EA031177B1 (ja) |
EC (2) | ECSP11010826A (ja) |
ES (2) | ES2654543T3 (ja) |
GT (4) | GT201100011DA (ja) |
HK (1) | HK1220981A1 (ja) |
HN (1) | HN2011000161A (ja) |
IL (7) | IL210356A (ja) |
MA (1) | MA32561B1 (ja) |
MX (5) | MX343250B (ja) |
NZ (5) | NZ707788A (ja) |
PE (7) | PE20141398A1 (ja) |
PH (1) | PH12015500782A1 (ja) |
PL (2) | PL3009449T3 (ja) |
PT (2) | PT3009449T (ja) |
SG (3) | SG10201608381SA (ja) |
UA (1) | UA106354C2 (ja) |
WO (1) | WO2010007533A2 (ja) |
ZA (1) | ZA201600335B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7458484B2 (ja) | 2019-12-04 | 2024-03-29 | チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド | 抗ヒトサイトメガロウイルス抗体及びその用途 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
CN102203133B (zh) | 2008-07-16 | 2015-01-07 | 生物医学研究学会 | 人巨细胞病毒中和抗体及其应用 |
CN102892782B (zh) | 2009-12-23 | 2015-01-14 | 4-抗体股份公司 | 针对人类巨细胞病毒的结合成员 |
CA2839420C (en) | 2010-06-16 | 2023-06-13 | Lawrence M. Kauvar | High affinity human antibodies to human cytomegalovirus (cmv) gb protein |
EP2590670B1 (en) | 2010-07-06 | 2017-08-23 | GlaxoSmithKline Biologicals SA | Methods of raising an immune response by delivery of rna |
PT2591114T (pt) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Imunização de mamíferos de grande porte com doses baixas de arn |
RS54489B1 (en) | 2010-07-06 | 2016-06-30 | Glaxosmithkline Biologicals Sa | LIPOSOMS WITH LIPIDS THAT HAVE IMPROVED PKA VALUE FOR RNA RELEASE |
PL3970742T3 (pl) | 2010-08-31 | 2022-09-19 | Glaxosmithkline Biologicals S.A. | Pegylowane liposomy do dostarczania rna kodującego immunogen |
WO2012047732A2 (en) * | 2010-09-29 | 2012-04-12 | Genentech, Inc. | Antibody compositions and methods of use |
US20140030292A1 (en) | 2010-10-11 | 2014-01-30 | Novartis Ag | Antigen delivery platforms |
US11896636B2 (en) | 2011-07-06 | 2024-02-13 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
EP2831119A1 (en) * | 2012-03-28 | 2015-02-04 | F. Hoffmann-La Roche AG | Anti-hcmv idiotypic antibodies and uses thereof |
WO2014018117A1 (en) | 2012-07-27 | 2014-01-30 | Diamond Don J | An mva vaccine for delivery of a ul128 complex and preventing cmv infection |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
CN109369808B (zh) | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
US20170296650A1 (en) | 2014-10-08 | 2017-10-19 | Novartis Ag | Combination of human cytomegalovirus neutralizing antibodies |
EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
HRP20211980T1 (hr) | 2015-04-07 | 2022-04-01 | Alector Llc | Protutijela protiv sortilina i postupci njihove upotrebe |
EP3347045A4 (en) | 2015-09-10 | 2019-08-28 | City of Hope | ANTIBODIES GENERATED BY MVA-GH / GL-PC VACCINE NEUTRALIZING THE INFECTIOUS POWER OF HUMAN CYTOMEGALOVIRUS AND ASSOCIATED METHODS |
CN105296588A (zh) * | 2015-10-16 | 2016-02-03 | 常州市第一人民医院 | 一种检测肾移植患者在术后感染巨细胞病毒危害程度的方法 |
US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
WO2017153954A1 (en) | 2016-03-11 | 2017-09-14 | Pfizer Inc. | Human cytomegalovirus gb polypeptide |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
BR112018071307A2 (pt) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | anticorpos agonistas que ligam cd40 humana e usos dos mesmos |
WO2017184562A1 (en) * | 2016-04-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Cmv neutralizing antigen binding proteins |
US11185582B2 (en) | 2016-05-09 | 2021-11-30 | Icahn School Of Medicine At Mount Sinai | Broadly neutralizing anti-human cytomegalovirus (HCMV) antibodies and methods of use thereof |
IL299099A (en) | 2016-06-27 | 2023-02-01 | Univ California | Combinations of cancer treatments |
WO2018031903A1 (en) | 2016-08-12 | 2018-02-15 | Streck, Inc. | Molecular reference controls |
CN106519027B (zh) * | 2016-11-11 | 2019-09-17 | 深圳先进技术研究院 | 抗h7n9全人源单克隆抗体5j13及其制法与应用 |
WO2018191603A1 (en) * | 2017-04-14 | 2018-10-18 | University Of Massachusetts | Targeting cell tropism receptors to inhibit cytomegalovirus infection |
CA3060019A1 (en) | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
CN107325178A (zh) * | 2017-06-29 | 2017-11-07 | 佛山市南海区普罗圣塔生物科技有限公司 | 一种抗人巨细胞病毒卵黄抗体及其制备方法和应用 |
WO2019183375A1 (en) * | 2018-03-22 | 2019-09-26 | Eureka Therapeutics, Inc. | Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof |
MX2020010913A (es) | 2018-04-17 | 2021-01-08 | Celldex Therapeutics Inc | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. |
HUE061841T2 (hu) | 2018-07-13 | 2023-08-28 | Alector Llc | Anti-sortilin antitestek és felhasználásuk módszerei |
CA3116175A1 (en) | 2018-10-17 | 2020-04-23 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
CN109580944A (zh) * | 2018-12-07 | 2019-04-05 | 潍坊医学院 | 一种人巨细胞病毒检测试纸及其制造方法 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CN109738631A (zh) * | 2019-01-21 | 2019-05-10 | 潍坊医学院 | 一种人巨细胞病毒IgM抗体检测试纸的制备方法 |
US20220119502A1 (en) * | 2019-02-28 | 2022-04-21 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Kawasaki disease antibodies identify hepacivirus peptides |
WO2020208082A1 (en) * | 2019-04-09 | 2020-10-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating cmv related diseases |
WO2021191836A1 (en) * | 2020-03-27 | 2021-09-30 | Glaxosmithkline Biologicals Sa | Hcvm pentamer binding antibodies |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
WO2023034950A2 (en) * | 2021-09-03 | 2023-03-09 | Icahn School Of Medicine At Mount Sinai | Anti-hcmv antibodies and antigen-binding fragments thereof |
CN116162154A (zh) * | 2022-10-21 | 2023-05-26 | 珠海泰诺麦博生物技术有限公司 | 抗人巨细胞病毒抗体及其用途 |
CN115947869B (zh) * | 2022-11-28 | 2023-12-12 | 广州佰芮慷生物科技有限公司 | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4294817A (en) * | 1977-11-25 | 1981-10-13 | International Diagnostic Technology, Inc. | Method of fluoro immunoassay |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US4313927A (en) | 1979-10-19 | 1982-02-02 | Ames-Yissum Ltd. | Immunoassay method for detecting viral antibodies in whole blood samples |
US4334016A (en) * | 1980-06-19 | 1982-06-08 | The Wistar Institute Of Anatomy And Biology | Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
FR2543570B1 (fr) | 1983-03-31 | 1985-08-09 | Pasteur Institut | Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains |
US4617379A (en) | 1983-06-14 | 1986-10-14 | Miles Laboratories, Inc. | High titer cytomegalovirus immune serum globulin |
GB8404368D0 (en) | 1984-02-20 | 1984-03-28 | Cogent Ltd | Monoclonal antibodies to human cytomegalovirus |
US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
FR2563630B1 (fr) | 1984-04-27 | 1988-02-19 | Pasteur Institut | Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux |
US4783399A (en) | 1984-05-04 | 1988-11-08 | Scripps Clinic And Research Foundation | Diagnostic system for the detection of cytomegalovirus |
US4743562A (en) | 1984-08-21 | 1988-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Purified human cytomegalovirus protein |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
DE3581400D1 (de) | 1984-09-28 | 1991-02-21 | Teijin Ltd | Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper. |
US4808518A (en) * | 1985-02-11 | 1989-02-28 | University Of Tennessee Research Corporation | Recovery of cytomegalovirus antigen and use thereof in an assay |
US4804627A (en) | 1985-05-09 | 1989-02-14 | Sloan-Kettering Institute For Cancer Research | Method for cloning lymphoblastoid cells |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
WO1987003602A1 (en) | 1985-12-06 | 1987-06-18 | Teijin Limited | Anticytomegaloviral human monoclonal antibody and process for its preparation |
US6162620A (en) | 1986-03-07 | 2000-12-19 | Cogent Limited | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5153311A (en) | 1986-11-24 | 1992-10-06 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus gCII |
US5126130A (en) * | 1986-11-24 | 1992-06-30 | The Childrens Hospital Incorporated | Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a |
LU86752A1 (fr) | 1987-01-30 | 1988-08-23 | Univ Bruxelles | Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus |
NZ226694A (en) | 1987-10-28 | 1994-04-27 | Oncogen | Human immunoglobulin produced by recombinant dna techniques |
US5180813A (en) | 1989-03-24 | 1993-01-19 | University Of Iowa Research Foundation | Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
WO1991004277A1 (en) | 1989-09-14 | 1991-04-04 | Children's Biomedical Research Institute | Monoclonal antibodies specific to cytomegalovirus glycoprotein |
WO1991005876A1 (en) | 1989-10-20 | 1991-05-02 | Children's Biomedical Research Institute | Human cytomegalovirus-specific monoclonal antibody cocktail |
GB9008223D0 (en) | 1990-04-11 | 1990-06-13 | Royal Free Hosp School Med | Improvements relating to the detection of viruses |
DE4035174A1 (de) | 1990-11-06 | 1992-05-07 | Biotest Ag | Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
JPH053794A (ja) | 1991-06-26 | 1993-01-14 | Green Cross Corp:The | 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞 |
DE4128684A1 (de) | 1991-08-29 | 1993-03-04 | Behringwerke Ag | Hcmv-spezifische peptide, mittel dazu und ihre verwendung |
EP0564735B1 (en) | 1992-04-10 | 1998-11-18 | Thomas Totterman | Method for detection of CMV infection |
SE9201281L (sv) | 1992-04-23 | 1993-10-24 | Bioinvent Int Ab | Nya humana monoklonala antikroppar och förfarande för framställning därav |
JPH05260961A (ja) | 1992-05-21 | 1993-10-12 | Teijin Ltd | サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ |
GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
DK0680333T3 (da) | 1993-01-21 | 2000-01-03 | Erna Miller | Forebyggelse og behandling af cytomegalovirus ved hjælp af aminopeptidase |
US5750106A (en) | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
CA2153790A1 (en) | 1993-01-28 | 1994-08-04 | Lars G. Ostberg | Human monoclonal antibodies to cytomegalovirus |
WO1994025490A1 (en) | 1993-04-30 | 1994-11-10 | The Scripps Research Institute | Human monoclonal antibodies to human cytomegalovirus, and methods therefor |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
EP0702083A3 (de) * | 1994-07-26 | 1997-01-15 | Biotest Ag | Polypeptide und Fusionsproteine bestehend aus dem UL 57 Leserahmen bzw. dem C-terminalen Bereich des Tegumentproteins pp150 aus HCMV, entsprechende Oligonucleotide und Nachweis reagentien |
US5502652A (en) | 1994-08-24 | 1996-03-26 | Hoggatt; Austin C. | Method and apparatus for measuring heat transfer in small diameter pipes using acoustic signals |
US5783383A (en) | 1995-05-23 | 1998-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of detecting cytomegalovirus (CMV) |
US6019980A (en) | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US5800981A (en) | 1996-02-22 | 1998-09-01 | University Of Limburg | Human cytomegalovirus antigen and its use |
DK0960336T3 (da) | 1996-07-12 | 2003-02-10 | Organon Teknika Bv | Peptidreagens til påvisning af humant cytomelagovirus (CMV) |
JP2000516617A (ja) | 1996-08-14 | 2000-12-12 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | アテローム性動脈硬化病変の出現を予防するか又は遅らせるための方法及び組成物 |
US7504493B2 (en) * | 1997-01-23 | 2009-03-17 | The John Hopkins University | Characterization of the yeast transcriptome |
US6156498A (en) | 1997-01-30 | 2000-12-05 | Cedars-Sinai Medical Center | Establishment of HHV-8+ lymphoma cell line, virus produced, antibody, diagnostic method and kit for detecting HHV-8 infection |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
WO1998057993A1 (en) | 1997-06-19 | 1998-12-23 | The Regents Of The University Of California | Secretory immunoglobulin produced by single cells and methods for making and using same |
NZ502626A (en) | 1997-07-18 | 2002-09-27 | Connaught Lab | Vaccines comprising a nucleic acid vector encoding the G protein of respiratory syncytial virus (RSV) |
US20030180257A1 (en) | 1997-11-14 | 2003-09-25 | Mark Parrington | Alphavirus vectors for paramyxovirus vaccines |
DE19756214C1 (de) | 1997-12-17 | 1999-02-25 | Biotest Ag | Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie |
EP1061943B1 (en) | 1998-03-12 | 2002-10-23 | Genentech, Inc. | Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases |
ATE249846T1 (de) | 1998-06-29 | 2003-10-15 | Wolfgang Bergter | Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern |
RU2133472C1 (ru) | 1998-09-16 | 1999-07-20 | Унитарное государственное Московское предприятие по производству бактерийных препаратов | Способ диагностики активной стадии цитомегаловирусной инфекции человека |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
ATE488583T1 (de) | 2001-02-21 | 2010-12-15 | Wistar Inst | Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält |
ITMI20012160A1 (it) | 2001-10-18 | 2003-04-18 | Edoardo Marchisio | Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test |
CN1188427C (zh) * | 2001-12-07 | 2005-02-09 | 暨南大学 | 检测hcmv抗体的重组嵌合肽抗原及其产生方法 |
US6828113B2 (en) | 2002-03-21 | 2004-12-07 | Cornell Research Foundation, Inc. | IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection |
KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
CA2480811A1 (en) | 2002-04-01 | 2003-10-16 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
TWI270088B (en) | 2002-11-29 | 2007-01-01 | Furukawa Electric Co Ltd | Insulated wire and resin dispersion |
RU2239453C2 (ru) | 2002-12-03 | 2004-11-10 | Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" | Препарат иммуноглобулина человека против цитомегаловируса и способ его получения |
CN1445243A (zh) * | 2002-12-13 | 2003-10-01 | 中国疾病控制中心病毒病预防控制所 | 抗人巨细胞病毒人源中和性基因工程Fab抗体 |
WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
US20040228842A1 (en) | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
US20060216302A1 (en) | 2003-02-28 | 2006-09-28 | Robert Root-Bernstein | Immunological markers |
KR101335079B1 (ko) | 2004-06-21 | 2013-12-12 | 메다렉스, 엘.엘.시. | 인터페론 알파 수용체 1 항체 및 그의 용도 |
AU2005263015A1 (en) | 2004-07-09 | 2006-01-19 | Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. | Differences in intestinal gene expression profiles |
BE1016287A6 (nl) | 2004-07-14 | 2006-07-04 | Picanol Nv | Gaapvormingsonderdeel voor een weefmachine en weefmachine. |
US7976845B2 (en) | 2004-11-29 | 2011-07-12 | The Council Of The Queensland Institute Of Medical Research | Human cytomegalovirus immunotherapy |
RU2394839C2 (ru) | 2004-12-21 | 2010-07-20 | Астразенека Аб | Антитела против ангиопоэтина-2 и их применение |
EP1861424B1 (en) | 2005-03-14 | 2011-03-30 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Human monoclonal antibodies against hendra and nipah viruses |
NZ563639A (en) | 2005-06-29 | 2009-12-24 | Compumedics Ltd | Sensor assembly with conductive bridge |
JP5142458B2 (ja) * | 2005-06-30 | 2013-02-13 | キヤノン株式会社 | 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法 |
ES2367322T3 (es) | 2005-12-16 | 2011-11-02 | Ribovax Biotechnologies Sa | Métodos para obtener células inmortalizadas que secretan anticuerpos. |
JPWO2007094423A1 (ja) | 2006-02-15 | 2009-07-09 | 株式会社イーベック | ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
EA200870555A1 (ru) * | 2006-05-19 | 2009-04-28 | Тева Фармасьютикал Индастриз, Лтд. | Слитые белки, их применение и способы их получения |
US7704510B2 (en) | 2006-06-07 | 2010-04-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
AU2007331463B2 (en) | 2006-12-15 | 2014-03-27 | Ribovax Biotechnologies Sa | Antibodies against human cytomegalovirus (hCMV) |
US7947274B2 (en) * | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
GB0700133D0 (en) * | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
WO2008120203A2 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases |
US20080248042A1 (en) | 2007-04-05 | 2008-10-09 | Irccs Centro Di Riferimento Oncologico Di Aviano, | Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc |
EP2190876A1 (en) | 2007-08-22 | 2010-06-02 | Ribovax Biotechnologies SA | Antibodies against human cytomegalovirus (hcmv) |
US7763261B2 (en) * | 2007-12-19 | 2010-07-27 | Dcb-Usa Llc | Anti-human cytomegalovirus antibodies |
WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
CN102203133B (zh) | 2008-07-16 | 2015-01-07 | 生物医学研究学会 | 人巨细胞病毒中和抗体及其应用 |
KR20150002895A (ko) | 2008-07-16 | 2015-01-07 | 인스티튜트 포 리서치 인 바이오메드슨 | 인간 사이토메갈바이러스 중화 항체 및 이의 용도 |
-
2009
- 2009-07-15 CN CN200980129827.XA patent/CN102203133B/zh not_active Expired - Fee Related
- 2009-07-15 EA EA201170205A patent/EA031177B1/ru not_active IP Right Cessation
- 2009-07-15 SG SG10201608381SA patent/SG10201608381SA/en unknown
- 2009-07-15 KR KR1020117001825A patent/KR101356350B1/ko active IP Right Grant
- 2009-07-15 EP EP17151249.4A patent/EP3178845A1/en not_active Withdrawn
- 2009-07-15 ES ES09745098.5T patent/ES2654543T3/es active Active
- 2009-07-15 MX MX2013011719A patent/MX343250B/es unknown
- 2009-07-15 UA UAA201100565A patent/UA106354C2/ru unknown
- 2009-07-15 BR BRPI0916443A patent/BRPI0916443A2/pt not_active Application Discontinuation
- 2009-07-15 PE PE2014000661A patent/PE20141398A1/es not_active Application Discontinuation
- 2009-07-15 SG SG10201706350PA patent/SG10201706350PA/en unknown
- 2009-07-15 PL PL15194590T patent/PL3009449T3/pl unknown
- 2009-07-15 CA CA2730776A patent/CA2730776C/en not_active Expired - Fee Related
- 2009-07-15 US US13/003,603 patent/US8603480B2/en active Active
- 2009-07-15 NZ NZ707788A patent/NZ707788A/en not_active IP Right Cessation
- 2009-07-15 MX MX2013011716A patent/MX343490B/es unknown
- 2009-07-15 CR CR20160355A patent/CR20160355A/es unknown
- 2009-07-15 ES ES15194590.4T patent/ES2682596T3/es active Active
- 2009-07-15 EP EP09745098.5A patent/EP2352759B1/en active Active
- 2009-07-15 PT PT151945904T patent/PT3009449T/pt unknown
- 2009-07-15 EP EP15194590.4A patent/EP3009449B1/en active Active
- 2009-07-15 NZ NZ591056A patent/NZ591056A/xx not_active IP Right Cessation
- 2009-07-15 MX MX2013011720A patent/MX338067B/es unknown
- 2009-07-15 NZ NZ60349809A patent/NZ603498A/en not_active IP Right Cessation
- 2009-07-15 WO PCT/IB2009/006641 patent/WO2010007533A2/en active Application Filing
- 2009-07-15 PE PE2014000171A patent/PE20140882A1/es active IP Right Grant
- 2009-07-15 PE PE2014000665A patent/PE20141434A1/es not_active Application Discontinuation
- 2009-07-15 PE PE2014000662A patent/PE20141432A1/es not_active Application Discontinuation
- 2009-07-15 PE PE2011000035A patent/PE20110413A1/es active IP Right Grant
- 2009-07-15 MX MX2011000543A patent/MX2011000543A/es active IP Right Grant
- 2009-07-15 AU AU2009272284A patent/AU2009272284C1/en not_active Ceased
- 2009-07-15 NZ NZ60349909A patent/NZ603499A/en not_active IP Right Cessation
- 2009-07-15 NZ NZ619953A patent/NZ619953A/en not_active IP Right Cessation
- 2009-07-15 JP JP2011518030A patent/JP5422649B2/ja not_active Expired - Fee Related
- 2009-07-15 CA CA3022196A patent/CA3022196A1/en not_active Abandoned
- 2009-07-15 PL PL09745098T patent/PL2352759T3/pl unknown
- 2009-07-15 CN CN201410204215.5A patent/CN103980363B/zh not_active Expired - Fee Related
- 2009-07-15 US US12/503,822 patent/US8124093B2/en not_active Expired - Fee Related
- 2009-07-15 PT PT97450985T patent/PT2352759T/pt unknown
- 2009-07-15 DK DK09745098.5T patent/DK2352759T3/en active
- 2009-07-15 SG SG2013050927A patent/SG191699A1/en unknown
- 2009-07-15 CN CN201611150943.8A patent/CN106924729B/zh not_active Expired - Fee Related
- 2009-07-15 PE PE2014000667A patent/PE20141435A1/es not_active Application Discontinuation
- 2009-07-15 DK DK15194590.4T patent/DK3009449T3/en active
- 2009-07-15 PE PE2014000664A patent/PE20141433A1/es not_active Application Discontinuation
-
2010
- 2010-12-29 IL IL210356A patent/IL210356A/en active IP Right Grant
-
2011
- 2011-01-14 GT GT201100011DA patent/GT201100011DA/es unknown
- 2011-01-14 HN HN2011000161A patent/HN2011000161A/es unknown
- 2011-01-14 GT GT201100011CM patent/GT201100011CA/es unknown
- 2011-01-14 CL CL2011000084A patent/CL2011000084A1/es unknown
- 2011-01-14 GT GT201100011BL patent/GT201100011BA/es unknown
- 2011-01-14 MX MX2013011718A patent/MX340315B/es unknown
- 2011-01-14 GT GT201100011AK patent/GT201100011AA/es unknown
- 2011-01-17 CU CU2011000009A patent/CU23953B1/es unknown
- 2011-02-11 MA MA33614A patent/MA32561B1/fr unknown
- 2011-02-14 EC ECSP11010826 patent/ECSP11010826A/es unknown
- 2011-02-14 EC ECSP11010827 patent/ECSP11010827A/es unknown
- 2011-02-15 CO CO11017912A patent/CO6351801A2/es active IP Right Grant
- 2011-02-16 CR CR20110091A patent/CR20110091A/es unknown
- 2011-12-28 US US13/338,934 patent/US8287870B2/en active Active
- 2011-12-28 US US13/338,905 patent/US8298539B2/en active Active
-
2012
- 2012-09-10 US US13/608,726 patent/US8435524B2/en active Active
-
2013
- 2013-04-16 US US13/863,782 patent/US8765132B2/en active Active
- 2013-10-22 JP JP2013218791A patent/JP5807050B2/ja not_active Expired - Fee Related
- 2013-12-04 US US14/096,283 patent/US9221897B2/en not_active Expired - Fee Related
- 2013-12-23 US US14/138,531 patent/US9127049B2/en not_active Expired - Fee Related
-
2014
- 2014-05-16 CL CL2014001293A patent/CL2014001293A1/es unknown
- 2014-05-29 IL IL232865A patent/IL232865A/en active IP Right Grant
- 2014-05-29 IL IL232862A patent/IL232862A/en active IP Right Grant
- 2014-05-29 IL IL232864A patent/IL232864A/en active IP Right Grant
- 2014-05-29 IL IL232863A patent/IL232863A/en active IP Right Grant
- 2014-05-29 IL IL232861A patent/IL232861A/en active IP Right Grant
-
2015
- 2015-04-08 PH PH12015500782A patent/PH12015500782A1/en unknown
- 2015-04-14 JP JP2015082325A patent/JP6062477B2/ja not_active Expired - Fee Related
- 2015-04-22 IL IL238421A patent/IL238421A/en active IP Right Grant
- 2015-07-31 US US14/815,162 patent/US9249213B2/en not_active Expired - Fee Related
- 2015-11-23 US US14/949,161 patent/US9365636B1/en active Active
- 2015-12-17 US US14/973,409 patent/US9371372B2/en active Active
-
2016
- 2016-01-15 ZA ZA2016/00335A patent/ZA201600335B/en unknown
- 2016-05-13 US US15/154,178 patent/US9527902B2/en active Active
- 2016-05-17 US US15/156,786 patent/US9491906B2/en active Active
- 2016-06-01 CL CL2016001340A patent/CL2016001340A1/es unknown
- 2016-07-27 HK HK16108977.2A patent/HK1220981A1/zh not_active IP Right Cessation
- 2016-10-04 US US15/284,799 patent/US9725502B2/en active Active
- 2016-11-22 US US15/358,845 patent/US9796771B2/en not_active Expired - Fee Related
- 2016-11-22 US US15/358,868 patent/US9796772B2/en not_active Expired - Fee Related
- 2016-12-14 JP JP2016241815A patent/JP6345753B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-29 US US15/637,513 patent/US9803000B1/en not_active Expired - Fee Related
- 2017-09-27 US US15/716,818 patent/US10040845B2/en active Active
-
2018
- 2018-05-23 JP JP2018098457A patent/JP6703037B2/ja not_active Expired - Fee Related
- 2018-07-02 US US16/025,296 patent/US10414817B2/en not_active Expired - Fee Related
-
2019
- 2019-07-31 US US16/527,836 patent/US10889632B2/en active Active
-
2020
- 2020-09-03 US US17/011,934 patent/US20210087257A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7458484B2 (ja) | 2019-12-04 | 2024-03-29 | チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド | 抗ヒトサイトメガロウイルス抗体及びその用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011527902A5 (ja) | ||
JP2011527899A5 (ja) | ||
CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
WO2021244089A1 (zh) | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 | |
JP2022177090A5 (ja) | ||
JP2018521638A5 (ja) | ||
JP2020536488A5 (ja) | ||
RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
JP2010516229A5 (ja) | ||
RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
RU2635999C2 (ru) | Антитела, подходящие для пассивной иммунизации против гриппа | |
JP2012501669A5 (ja) | ||
JP2019516348A (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
JP2012525829A5 (ja) | ||
JP2012501670A5 (ja) | ||
CN113045647B (zh) | 新冠病毒SARS-CoV-2的中和性抗体及其应用 | |
WO2008031133A3 (en) | Borrelia antigens | |
JP2013520984A5 (ja) | ||
JP2016516400A5 (ja) | ||
JP2018520334A5 (ja) | ||
JP2012526542A5 (ja) | ||
JP2017534259A5 (ja) | ||
RU2009144280A (ru) | АНТАГОНИСТЫ CRIg | |
JP2017532005A5 (ja) | ||
JP2007504812A5 (ja) |